All rights, including copyright, in this content/article provided by are owned or controlled by Mosaic Media Ventures Private Limited. This content/article is provided by Mosaic Media Ventures Private Limited and not by Reuters. and American Access Care while 16 investments were made in healthcare technology companies such as Alma Lasers, Ltd, Cypress Pharmceutical Inc. So far, TA Associates, which has invested in 400 companies, invested in about 28 healthcare service firms globally such as Twin Med LLC, Quotient Bioscience Ltd, Youth and Family Centered Services, Inc.
TA Associates last year closed its new $4-billion fund, TA XI, L.P. It has also invested in companies like Idea Cellular Ltd and GlobeOp Financial Services, a specialist BPO company. This year, TA Associates has invested $45 million (Rs 200 crore) in Gurgaon-based Micromax Informatics Ltd., which develops mobile phone solutions and wireless technologies. Till date in 2010, about 13 PE deals worth $366 million took place in healthcare& pharma space. We are today in discussions for advising on two healthcare investments and hoping to execute on both deals in the coming months.”Īccording to VCCEdge data, since 1996, 137 PE deals worth $2.3 billion took place in Indian healthcare& pharmaceuticals space. In an earlier interview with VCCircle, Naveen Wadhera, director, TA Associates, had said, “Healthcare, more broadly, is an area we are very bullish on and eager to participate in. It has employee strength of over 1,000 serves around 4 million customers every year, according to the company website. Lal PathLabs offers more than 1,650 different types of tests and has a pan India presence, in the form of state-of-the-art laboratories and patient service centres. Mails sent to Sandeep Singhal, MD, Sequoia Capital and Naveen Wadhera, director, TA Associates did not elicit any response till the report is published.Įstablished in 1949, Dr. Before joining Dr Lal PathLabs in 2005, Manchanda led the International & Innovation group of the Consumer Healthcare Division at Ranbaxy. OP Manchanda, CEO, Dr Lal PathLabs, told VCCircle, “This will be an exciting deal for TA Associates as Dr Lal PathLabs grows annually at 40-45% rate which is 2 times higher than India’s pathology business, which is growing at 20% annually.” However, he declined to disclose the size of the deal.
0 kommentar(er)
